We then extended our analysis of the correlation between IDH status and drug sensitivity profiles...ICC harboring IDH2R172K and KrasG12D mutations (SS49 cells) or KrasG12D mutation and p53 deletion (425 and 537 cells)...The IDHm ICC SS49 cells were highly sensitive to dasatinib (IC50 = 3.6 nM, versus > 100 nM in 425 and 537 cells) and to a lesser extent saracatinib, while the effects of bosutinib and ponatinib were comparable between genotypes, in line with the effects seen in human ICC cells.